SCHEMBL2187703

SCHEMBL2187703

CC(C)([C@@H]1CCN(c2ncc(C(F)(F)F)cc2F)C(=O)C1)S(=O)(=O)c1cccc(OC(F)(F)F)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1B Q00975 4/20 0.43
CYP3A4 P08684 3/20 0.43
SLC6A9 P48067 4/20 0.39
KCNH2 Q12809 3/20 0.39
PIM1 P11309 1/20 0.38
NR1I2 O75469 1/20 0.38
MCHR1 Q99705 1/20 0.36
CXCR3 P49682 3/20 0.36
AKR1C3 P42330 1/20 0.36
RORC P51449 1/20 0.35
OPRM1 P35372 1/20 0.35
OPRL1 P41146 1/20 0.35
KIT P10721 1/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
CYP1A2 P05177 1/20 0.34
KDM2B Q8NHM5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2188512 1.00 CACNA1B (0.43) CACNA1BCYP3A4SLC6A9KCNH2PIM1
SCHEMBL2190611 0.90 CYP3A4 (0.47) CACNA1BCYP3A4SLC6A9KCNH2NR1I2
SCHEMBL1710957 0.90 CYP3A4 (0.47) CACNA1BCYP3A4SLC6A9KCNH2NR1I2
SCHEMBL1728213 0.90 CYP3A4 (0.47) CACNA1BCYP3A4SLC6A9KCNH2NR1I2
SCHEMBL2190571 0.87 CACNA1B (0.46) CACNA1BCYP3A4SLC6A9KCNH2NR1I2
SCHEMBL2189367 0.87 CACNA1B (0.46) CACNA1BCYP3A4SLC6A9KCNH2NR1I2
SCHEMBL2189349 0.86 CACNA1B (0.44) CACNA1BCYP3A4PIM1NR1I2MCHR1
SCHEMBL2190550 0.86 CACNA1B (0.44) CACNA1BCYP3A4PIM1NR1I2MCHR1
SCHEMBL2188591 0.83 CACNA1B (0.41) CACNA1BCYP3A4KCNH2PIM1MCHR1
SCHEMBL2189927 0.83 CACNA1B (0.41) CACNA1BCYP3A4KCNH2PIM1MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US claimed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS CHAKRAVARTY PRASUN K 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172236-A1 SUBSTITUTED ARYL SULFONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, TRPA1, CACNA1D CACNA1B 23/4885CYP3A4 939/4885SLC6A9 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.